Last reviewed · How we verify

IPTp-sulphadoxine-pyrimethamine plus metronidazole

London School of Hygiene and Tropical Medicine · Phase 3 active Small molecule

IPTp-sulphadoxine-pyrimethamine plus metronidazole is a Antifolate antimalarial + nitroimidazole antibiotic Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently in Phase 3 development for Malaria prevention in pregnant women (intermittent preventive treatment), Reduction of adverse pregnancy outcomes associated with malaria infection. Also known as: Fansidar, Flagyl.

This combination therapy prevents malaria and treats bacterial/parasitic infections in pregnant women through antifolate antimalarial activity and broad-spectrum antimicrobial action.

This combination therapy prevents malaria and treats bacterial/parasitic infections in pregnant women through antifolate antimalarial activity and broad-spectrum antimicrobial action. Used for Malaria prevention in pregnant women (intermittent preventive treatment), Reduction of adverse pregnancy outcomes associated with malaria infection.

At a glance

Generic nameIPTp-sulphadoxine-pyrimethamine plus metronidazole
Also known asFansidar, Flagyl
SponsorLondon School of Hygiene and Tropical Medicine
Drug classAntifolate antimalarial + nitroimidazole antibiotic
TargetPlasmodial dihydrofolate reductase (SP); bacterial/parasitic DNA (metronidazole)
ModalitySmall molecule
Therapeutic areaInfectious Disease / Obstetrics
PhasePhase 3

Mechanism of action

Sulphadoxine-pyrimethamine (SP) is an antifolate combination that inhibits plasmodial dihydrofolate reductase, preventing malaria parasites from synthesizing nucleotides. Metronidazole is a nitroimidazole that disrupts bacterial and parasitic DNA, providing additional coverage against anaerobic bacteria and protozoa. IPTp (intermittent preventive treatment in pregnancy) uses this combination to reduce malaria infection and associated adverse pregnancy outcomes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about IPTp-sulphadoxine-pyrimethamine plus metronidazole

What is IPTp-sulphadoxine-pyrimethamine plus metronidazole?

IPTp-sulphadoxine-pyrimethamine plus metronidazole is a Antifolate antimalarial + nitroimidazole antibiotic drug developed by London School of Hygiene and Tropical Medicine, indicated for Malaria prevention in pregnant women (intermittent preventive treatment), Reduction of adverse pregnancy outcomes associated with malaria infection.

How does IPTp-sulphadoxine-pyrimethamine plus metronidazole work?

This combination therapy prevents malaria and treats bacterial/parasitic infections in pregnant women through antifolate antimalarial activity and broad-spectrum antimicrobial action.

What is IPTp-sulphadoxine-pyrimethamine plus metronidazole used for?

IPTp-sulphadoxine-pyrimethamine plus metronidazole is indicated for Malaria prevention in pregnant women (intermittent preventive treatment), Reduction of adverse pregnancy outcomes associated with malaria infection.

Who makes IPTp-sulphadoxine-pyrimethamine plus metronidazole?

IPTp-sulphadoxine-pyrimethamine plus metronidazole is developed by London School of Hygiene and Tropical Medicine (see full London School of Hygiene and Tropical Medicine pipeline at /company/london-school-of-hygiene-and-tropical-medicine).

Is IPTp-sulphadoxine-pyrimethamine plus metronidazole also known as anything else?

IPTp-sulphadoxine-pyrimethamine plus metronidazole is also known as Fansidar, Flagyl.

What drug class is IPTp-sulphadoxine-pyrimethamine plus metronidazole in?

IPTp-sulphadoxine-pyrimethamine plus metronidazole belongs to the Antifolate antimalarial + nitroimidazole antibiotic class. See all Antifolate antimalarial + nitroimidazole antibiotic drugs at /class/antifolate-antimalarial-nitroimidazole-antibiotic.

What development phase is IPTp-sulphadoxine-pyrimethamine plus metronidazole in?

IPTp-sulphadoxine-pyrimethamine plus metronidazole is in Phase 3.

What are the side effects of IPTp-sulphadoxine-pyrimethamine plus metronidazole?

Common side effects of IPTp-sulphadoxine-pyrimethamine plus metronidazole include Gastrointestinal disturbance, Metallic taste (metronidazole), Allergic reactions (sulphonamide sensitivity), Peripheral neuropathy (rare).

What does IPTp-sulphadoxine-pyrimethamine plus metronidazole target?

IPTp-sulphadoxine-pyrimethamine plus metronidazole targets Plasmodial dihydrofolate reductase (SP); bacterial/parasitic DNA (metronidazole) and is a Antifolate antimalarial + nitroimidazole antibiotic.

Related